News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Diamyd Medical AB: Diamyd® Phase III Study Approved by Six European Countries
November 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Today Diamyd Medical (Pink Sheets:DMYDY)(STO:DIAMB) reported that six European countries have approved the initiation of a Phase III study with the Diamyd® diabetes vaccine for type 1 diabetes.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Manufacturing
Sun Pharma stops eye-care drug production at Indian plant amid quality issues
November 2, 2026
·
2 min read
·
Nick Paul Taylor
Multiple sclerosis
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
November 2, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Can Saudi Arabia’s burgeoning biotech hub withstand geopolitical pressures?
November 2, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Earnings
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
October 30, 2026
·
3 min read
·
Gabrielle Masson
